Skip to main content
ENDO 2026 Main banner

Hans Johnson, MBChB Mres MSc

UNIVERSITY OF BRISTOL
Bristol, United Kingdom

Dr Hans Johnson is physician and Research Lead at Voy, a UK digital health platform delivering GLP-1/GIP pharmacotherapy and testosterone replacement therapy at scale. At Voy, he leads a real-world evidence programme spanning obesity pharmacotherapy, cardiometabolic outcomes, and male hormone health, drawing on a dataset of over 500,000 patients across UK, Brazil, Germany and soon India. His work on digital engagement and GLP-1/GIP outcomes was published in Diabetes, Obesity and Metabolism (2026), and his TRT research has been presented at EAU and AUA. He holds academic affiliations at the Universities of Oxford and is a clinical lecturer in applied AI at University of Bristol, and collaborates with partners at Harvard, Cambridge, Oxford, UCL, Imperial, Baylor and European Universities.

Disclosure information not submitted.

Presentation(s):